Intelligence Driven Advisers LLC Has $535,000 Holdings in Novo Nordisk A/S (NYSE:NVO)

Intelligence Driven Advisers LLC raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 19.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,666 shares of the company’s stock after buying an additional 762 shares during the quarter. Intelligence Driven Advisers LLC’s holdings in Novo Nordisk A/S were worth $535,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Jennison Associates LLC raised its position in shares of Novo Nordisk A/S by 100.3% during the third quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock worth $2,129,761,000 after purchasing an additional 11,727,507 shares during the period. FMR LLC raised its position in shares of Novo Nordisk A/S by 122.7% during the third quarter. FMR LLC now owns 12,077,501 shares of the company’s stock worth $1,098,328,000 after purchasing an additional 6,654,614 shares during the period. Morgan Stanley raised its position in shares of Novo Nordisk A/S by 96.5% during the third quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock worth $838,021,000 after purchasing an additional 4,526,199 shares during the period. Loomis Sayles & Co. L P raised its position in shares of Novo Nordisk A/S by 91.7% during the third quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock worth $827,354,000 after purchasing an additional 4,350,862 shares during the period. Finally, Polen Capital Management LLC acquired a new position in shares of Novo Nordisk A/S during the third quarter worth approximately $718,995,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

NYSE:NVO traded down $3.96 during trading on Thursday, reaching $125.25. The company’s stock had a trading volume of 5,895,505 shares, compared to its average volume of 4,819,019. The firm has a market cap of $562.06 billion, a price-to-earnings ratio of 46.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.43. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. The firm has a 50 day moving average of $127.22 and a 200-day moving average of $112.70. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. The firm had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. Research analysts expect that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on NVO. BMO Capital Markets initiated coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. UBS Group initiated coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target for the company. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.